More research is needed to understand how astaxanthin works on hormones
Therefore, while the Biden administrations proposed reinterpretation of Medicare Part D coverage of weight loss medications would allow for access to such therapies to approximately 3.4 million Medicare beneficiaries who have obesity, for budgetary reasons its unclear if the incoming Trump administration will go along with it
Before we go and find out what the big deal with Matrixyl 3000 is, let's just focus on Palmitoyl Tripeptide-1 itself for a bit
"If we are offering something and then taking it away and suddenly making it financially only available to people who can afford those high prices, you are going to cause a massive divide and further inequality," according to Dr Mayoni Gooneratne, who works in the UK but also but also co-founded Guernsey Women's Wellness
Compounding benefits take hold
The FDA has never approved this combination, and clinical literature documenting its safety is essentially nonexistent